ITRASKIN ® 120 ml

Itraskin^®, oral suspension, is recommended for the treatment of fungal infections caused by microorganisms susceptible to Itraconazole, such as skin dermatophytosis caused by Microsporum canis in cats, dermatitis caused by Malassezia pachydermatis in dogs and systemic infections of fungal origin, such as, histoplasmosis, cryptococcosis, blastomycosis and sporotrichosis.

Category: Drag Pharma

Product Description

SPECIES

Dogs and cats.

DOSAGE FORM

Oral suspension.

THERAPEUTIC ACTION

Antifungal.

COMPOSITION

Each mL of suspension contains:
Itraconazole……………….20 mg
Excipients q.s.p…………….1 mL

PROPERTIES

Itraconazole is a synthetic antifungal agent, belonging to the family of azole derivatives. It was introduced in the 90s in order to broaden the antifungal spectrum, increase its potency compared to other azoles and reduce adverse effects at the digestive level, especially in prolonged therapies.
The antifungal action of Itraconazole is generated through a multiple mechanism initiated by the inhibition of two cytochromes P450 involved in the biosynthesis of Ergosterol: CYP51 (sterol-14 alpha demethylase) and CYP61 (Delta 22-denaturase). Ergosterol is an essential component of the plasma membrane of fungi.

INDICATIONS

ROUTE OD ADMINISTRATION AND DOSAGE

Orally.

Recommended dose:

Cats:

Pathology	Dose
Dermatophytosis by Microsporum canis:	1 mL every 2 Kg of weight (equivalent to 10 mg/kg) every 24 hours, for 4 weeks. It is recommended to continue the therapy until mycological cure or lack of dermatophyte isolation in three consecutive weekly cultures.
Systemic fungal infections (histoplasmosis, cryptococcosis, blastomycosis, etc.):		0.5 mL every 2 of weight (equivalent to 5 mg/kg) every 12 hours, or 1 ml every 2 Kg of weight (equivalent to 10 mg/kg) every 24 hours. The therapy should be continued for 2 to 3 months or until 1 month after the resolution of the clinical signs of the animal.

Dogs:

Patología	Dosis
Dermatitis por Malassezia pachydermatis:	2,5 mL cada 10 kg de peso (equivalentes a 5 mg/kg) cada 24 horas, por 3 semanas.
Enfermedades fúngicas sistémicas (blastomicosis, histoplasmosis, esporotricosis, etc.):	2,5 mL cada 10 kg de peso (equivalentes a 5 mg/kg) cada 24 horas, por 2 a 3 meses, o hasta después de 1 mes de la resolución de los signos clínicos del animal.

DRUG INTERACTIONS

Itraconazole absorption is reduced by administration in conjunction with proton pump inhibitor antacids (Omeprazole) and H2 blockers (Cimetidine, Ranitidine, etc.) or Didanosine.
Itraconazole can increase prothrombin times in patients receiving Warfarin or other coumarin anticoagulants. Rifampin can increase the metabolism of Itraconazole.
Itraconazole can increase the serum levels of oral antidiabetic agents (eg Chlorpropamide, Glipizide etc.), which can lead to hypoglycemia.
Do not use in conjunction with Cisapride, as it can cause ventricular arrhythmias.
Itraconazole interacts with certain antihistamines (Ternadine, Astemizole), Benzodiazepines, calcium channel blockers, anticonvulsants, some antimicrobials and Cyclosporine.
It is not recommended to use concomitantly with anticholinergics.

CONTRAINDICATIONS

Do not use in patients with hypersensitivity to itraconazole or other azole agents.
Do not use in patients with hepatic impairment or hypochlorhydria.
Do not use in females during the gestation and lactation period.
Do not use in dogs and cats under 2 months of age.

PRECAUTIONS

It is recommended to administer the drug in conjunction with food, to increase its bioavailability.
It is recommended to monitor the appetite of treated individuals.
In prolonged treatments or in patients with particular risk conditions, it is recommended to monitor liver enzymes routinely (monthly ALT).

SPECIAL PRECAUTIONS FOR THE OPERATOR

Wash your hands after administering the product.
In the case of contact with the eyes, it is recommended to wash with plenty of water for 15 minutes.
In case of accidental ingestion do not induce vomiting. Obtain medical attention if necessary.

WARNINGS

Keep out of the reach of children

ADVERSE EFFECTS

In dogs, the most common adverse effect is anorexia, especially with higher doses.Some cases may show signs of hepatotoxicity, in which case treatment should be discontinued at least temporarily. Liver damage is determined by increased ALT activity. Anorexia is often a symptomatic marker of toxicity and usually occurs in the second month of treatment. Some dogs treated with doses of 10 mg / kg may develop vasculitis or ulcerative skin lesions and edema of the limbs that may require a reduction of the dose to 5 mg / kg. These problems usually resolve after stopping the medication. In cats, adverse effects are dose related. Gastrointestinal effects (anorexia, weight loss, vomiting), hepatotoxicity (increased ALT, jaundice), and depression have been reported. If adverse effects occur and ALT is elevated, the drug should be discontinued. Enzyme hyperactivity in the absence of other signs does not necessarily require reducing the dose or stopping the medication. Once ALT levels normalize and other adverse effects decrease, and if necessary, the drug can be restarted at half the dose initially used with closer clinical supervision.